EdiGene
675 West Kendall Street, Mass Innovation Labs
Cambridge
MA
02142
United States
Tel: 617682-5731
32 articles with EdiGene
-
EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia
11/18/2022
EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it had completed the last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent β-thalassemia.
-
EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies
11/7/2022
EdiGene, Inc. announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass.
-
EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing Hematopoietic Stem Cell Therapy, at the 64th ASH Annual Meeting and Exposition
11/3/2022
EdiGene, Inc. announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent β-thalassemia at the 64th American Society of Hematology Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, Louisiana.
-
EdiGene to Present getools, a Data Analysis Software Toolkit for Advanced Analytics of DNA and RNA Editing Efficiency and Outcomes for Therapeutic Development at the ASGCT 25th Annual Meeting
5/2/2022
EdiGene, Inc., a global, clinical-stage biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, will present getools (gene editing data analysis toolkit) for advanced analytics of DNA and RNA editing efficiency and outcomes for therapeutic development at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
-
EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer
4/13/2022
EdiGene, Inc. said it has entered into a research collaboration with Peking University Cancer Hospital to understand gene mutation frequency and clinicopathologic features of patients with advanced colorectal cancer in China.
-
EdiGene Obtains Worldwide License from Boston Children’s Hospital to Methods and Compositions for Increasing Fetal Hemoglobin Levels to Treat Hemoglobinopathies
3/16/2022
EdiGene, Inc. entered a non-exclusive, worldwide license agreement with Boston Children’s Hospital for intellectual property related to methods and compositions for increasing fetal hemoglobin levels by disrupting BCL11A expression at the genomic level to treat hemoglobinopathies.
-
EdiGene Announces Publication by Company Scientific Founder in Nature Biotechnology of LEAPER™ 2.0, an Updated Version of the RNA Base Editing Technology Using Engineered Circular ADAR-recruiting RNAs
2/10/2022
EdiGene, Inc., a global biotechnology company, today announced its Scientific Founder Wensheng Wei’s lab at Peking University has published a research article in Nature Biotechnology on an upgraded version of LEAPER™ (Leveraging endogenous ADAR for programmable editing of RNA) that shows significantly improved efficiency and fidelity of RNA editing in vitro and in vivo.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies
2/9/2022
EdiGene, Inc. and Neukio Biotherapeutics announced an R&D collaboration to develop next-generation immune cell therapies.
-
EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs
2/8/2022
EdiGene, Inc. announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.
-
EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies
1/24/2022
EdiGene, Inc. announced a research and development collaboration with Haihe Laboratory of Cell Ecosystem to develop hematopoietic stem cell regenerative therapies and platform technology by combining resources and expertise from both sides.
-
EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies
11/9/2021
EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies
-
EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC)
11/4/2021
EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and HSC Transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
-
EdiGene Secures New Lab and Office Space for Its Growing U.S. R&D Center to Advance Gene-editing Based Therapies
11/2/2021
EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, has signed a lease for 14,000 square feet of lab and office space in the Greater Boston area to house the company’s growing U.S. R&D Center.
-
EdiGene Announces Clinical Sites Activation and First Patient Enrolled in Multicenter Phase I Clinical Trial of its Investigational Gene-editing Hematopoietic Stem Cell Therapy ET-01 for Patients with Transfusion Dependent β-thalassemia
9/8/2021
EdiGene, Inc., announced the first patient enrolled in multicenter Phase I clinical study of its investigational gene-editing hematopoietic stem cell therapy ET-01 for patients with transfusion dependent β-thalassemia at the Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, and activation of the investigational site at Nanfang Hospital of Southern Medical University in Guangzhou, Guangdong Province.
-
EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies
4/21/2021
EdiGene, Inc., announced the successful completion of an RMB 400 million Series B Plus financing. Loyal Valley Capital led the round and other new investors included BioTrack Capital and Sherpa Healthcare Partners, along with continued support by existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital and Kunlun Capital.
-
EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration
1/18/2021
EdiGene, Inc., announced the Center for Drug Evaluation of China National Medical Products Administration has approved the Company’s Investigational New Drug application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia.
-
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan
12/14/2020
EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced the appointment of Bo Zhang, Ph.D., as Head of the US Subsidiary, and Kehua Fan, M.D., as Head of Business Development.
-
Biopharma Money on the Move: October 7-14
10/15/2020
Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs. -
The Beijing-based biotech will use the Series B funds to further their hematopoietic disease and cancer therapies pipeline and expand team.